By Matt Grossman
Bristol Myers Squibb Co. said Friday that a trial examining Opdivo plus Yervoy as a first-line treatment in some head-and-neck-cancer patients didn't meet its primary endpoints.
The study was testing the drugs' use in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. The drugs showed a positive trend toward overall survival in some patients compared with another treatment regimen, but the primary endpoints weren't achieved.
The Food and Drug Administration and the European Medicines Agency have previously approved Opdivo on its own for use in metastatic squamous cell carcinoma of the head and neck. Yervoy has also been previously approved to treat other cancers.
Write to Matt Grossman at firstname.lastname@example.org
(END) Dow Jones Newswires